Japan's Takeda on the hunt for new drugs to support growth
Singapore
AFFORDABILITY of drugs is the single biggest challenge for not just governments looking to keep a lid on healthcare costs, but also for drug makers hunting for growth and pressured to find new treatments to cope with the rapid rise in patients' need for medicines.
The Asia-Pacific region alone bears 25 per cent of the global disease burden, and the problem is amplified by a fast-ageing population and rise in lifestyle-induced diseases in places including Korea and Taiwan, says Gordon Cameron, area vice-president, Asia-Pacific, at Takeda Pharmaceuticals.
Mr Cameron, who assumed his current r…
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Blackstone reports 1% rise in Q1 earnings
India’s Infosys misses fourth-quarter revenue estimates
UBS shuts some China private funds, will lay off staff: sources
China’s top lenders face 1.6 trillion yuan loss-absorbing capital shortfall by 2025, Fitch estimates
US dollar rally stalls after rare FX warning from finance chiefs
ROE target of 14% is ‘decent’ for UOB: CEO Wee Ee Cheong